American Journal of Kidney Diseases
Volume 53, Issue 4 , Pages 681-688 , April 2009

CKD as an Underrecognized Threat to Patient Safety

  • Jeffrey C. Fink, MD

      Affiliations

    • Department of Medicine, University of Maryland School of Pharmacy, Baltimore, MD
    • Department of Epidemiology, University of Maryland School of Pharmacy, Baltimore, MD
    • Corresponding Author InformationAddress correspondence to Jeffrey C. Fink, MD, Rm N3W143, 22 S Greene St, University of Maryland School of Medicine, Baltimore, MD 21201
    • ,
  • Jeanine Brown, MS

      Affiliations

    • Department of Medicine, University of Maryland School of Pharmacy, Baltimore, MD
    • ,
  • Van Doren Hsu, PharmD

      Affiliations

    • Department of Pharmaceutical Research Computing, University of Maryland School of Pharmacy, Baltimore, MD
    • ,
  • Stephen L. Seliger, MD

      Affiliations

    • Department of Medicine, University of Maryland School of Pharmacy, Baltimore, MD
    • Department of Epidemiology, University of Maryland School of Pharmacy, Baltimore, MD
    • ,
  • Loreen Walker, BS

      Affiliations

    • Department of Pharmaceutical Research Computing, University of Maryland School of Pharmacy, Baltimore, MD
    • ,
  • Min Zhan, PhD

      Affiliations

    • Department of Epidemiology, University of Maryland School of Pharmacy, Baltimore, MD

Received 8 October 2008 ,Accepted 22 December 2008.

References 

  1. Kohn KT, Corrigan JM, Donaldson MS. To Err is Human: Building a Safer Health System. Washington, DC: National Academy; 1999;
  2. Agency for Healthcare Research and Quality. AHRQ Quality Indicators—Guide to Patient Safety Indicators. Rockville, MD: Agency for Healthcare Quality and Research; 2003;
  3. Zhan C, Miller MR. Excess length of stay, charges, and mortality attributable to medical injuries during hospitalization. JAMA. 2003;290:1868–1874
  4. Zhan C, Kelley E, Yang HP, et al. Assessing patient safety in the United States: Challenges and opportunities. Med Care. 2005;43(suppl 3):SI42–SI47
  5. Leape LL, Berwick DM. Five years after To Err Is Human: What have we learned. JAMA. 2005;293:2384–2390
  6. HealthGrades. The Fifth Annual HealthGrades Patient Safety in American Hospitals Study. Golden, CO: Health Grades, Inc; 2008;
  7. Encinosa WE, Bernard DM. Hospital finances and patient safety outcomes. Inquiry. 2005;42:60–72
  8. Weiner BJ, Alexander JA, Baker LC, Shortell SM, Becker M. Quality improvement implementation and hospital performance on patient safety indicators. Med Care Res Rev. 2006;63:29–57
  9. Clement JP, Lindrooth RC, Chukmaitov AS, Chen HF. Does the patient's payer matter in hospital safety?. Med Care. 2007;45:131–138
  10. Coffey RM, Andrews RM, Moy E. Racial, ethnic, and socioeconomic disparities in estimates of AHRQ Patient Safety Indicators. Med Care. 2005;43:I48–I57
  11. Zhan C, Kelley E, Yang HP, et al. Assessing patient safety in the United States: Challenges and opportunities. Med Care. 2005;43(suppl 3):SI42–SI47
  12. Baker GR, Norton PG, Flintoft V, et al. The Canadian Adverse Events Study: The incidence of adverse events among hospital patients in Canada. CMAJ. 2004;170:1678–1686
  13. Donabedian A. Explorations in Quality Assessment and Monitoring: The Definition of Quality and Approaches to its Assessment. Ann Arbor, MI: Health Administration Press; 1980;
  14. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038–2047
  15. Saydah S, Eberhardt M, Rios-Burrows N, Williams D, Geiss L, Dorsey R. Prevalence of chronic kidney disease and associated risk factors—US, 1999-2004. MMWR Morbid Mortal Wkly Rep. 2007;56:161–165
  16. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164:659–663
  17. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–1305
  18. Nissenson AR, Collins AJ, Hurley J, Petersen H, Pereira BJG, Steinberg EP. Opportunities for improving the care of patients with chronic renal insufficiency: Current practice patterns. J Am Soc Nephrol. 2001;12:1713–1720
  19. Coresh J, Byrd-Holt D, Astor BC, et al. Chronic disease awareness, prevalence, and trends among US adults. J Am Soc Nephrol. 2005;16:180–188
  20. Stevens LA, Fares G, Fleming J, et al. Low rates of testing and diagnostic codes usage in a commercial clinical laboratory: Evidence for lack of physician awareness of chronic kidney disease. J Am Soc Nephrol. 2005;16:2439–2448
  21. Akbari A, Swedko PJ, Clark HD, et al. Detection of chronic kidney disease with laboratory reporting of estimated glomerular filtration rate and an education program. Arch Intern Med. 2004;164:1788–1792
  22. Seliger SL, Zhan M, Hsu VD, Walker LD, Fink JC. Chronic kidney disease adversely influences patient safety. J Am Soc Nephrol. 2008;19:2414–2419
  23. Chertow GM, Lee J, Kuperman GJ, et al. Guided medication dosing for inpatients with renal insufficiency. JAMA. 2001;286:2839–2844
  24. Blix HS, Viktil KK, Moger TA, Reikvam A. Use of renal risk drugs in hospitalized patients with impaired renal function—An underestimated problem?. Nephrol Dial Transplant. 2006;21:3164–3171
  25. Corsonello A, Pedone C, Corica F, et al. Concealed renal insufficiency and adverse drug reactions in elderly hospitalized patients. Arch Intern Med. 2005;165:790–795
  26. Salomon L, Deray G, Sandon MC, et al. Medication misuse in hospitalized patients with renal impairment. Int J Qual Health Care. 2003;15:331–335
  27. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004;351:585–592
  28. Weir MR. Are drugs that block the renin-angiotensin system effective and safe in patients with renal insufficiency?. Am J Hypertens. 1999;12(12 pt 3):195S–203S
  29. Snyder KW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes and advanced kidney disease. Semin Dial. 2004;17:365–370
  30. Biesenbach G, Raml A, Schemkal B, Eichbauer-Sturm G. Decreased insulin requirement in relationship to GFR in nephropathic type 1 and insulin-treated type 2 diabetic patients. Diabet Med. 2003;20:642–645
  31. Jung GJ, Gil HW, Yang JO, Lee EY, Hong SY. Severe hypermagnesemia causing quadriparesis in a CAPD patient. Perit Dial Int. 2008;28:206;(abstr)
  32. Zaman F, Abreo K. Severe hypermagnesemia as a result of laxative use in renal insufficiency. South Med J. 2003;96:102–103
  33. Hurst FP, Bohen EM, Osgard EM, et al. Association of oral sodium phosphate purgative use with acute kidney injury. J Am Soc Nephrol. 2007;18:3192–3198
  34. Parfrey PS, Griffiths SM, Barrett BJ, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both: A prospective controlled study. N Engl J Med. 1989;320:143–149
  35. Solomon R. Contrast-medium-induced acute renal failure. Kidney Int. 1998;53:230–242
  36. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: Risk factors and incidence estimation. Radiology. 2007;243:148–157
  37. Sosnov J, Lessard D, Goldberg RJ, Yarzebski J, Gore JM. Differential symptoms of acute myocardial infarction in patients with kidney disease: A community-wide perspective. Am J Kidney Dis. 2006;47:378–384
  38. Gibson CM, Dumaine RL, Gelfand EV, et al. Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome: Observations in 13,307 patients in five TIMI trials. Eur Heart J. 2004;25:1998–2005
  39. Sadeghi HM, Stone GW, Grines CL, et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation. 2003;108:2769–2775
  40. Wilcox CS. Metabolic and adverse effects of diuretics. Semin Nephrol. 1999;19:557–568
  41. Kittleson M, Hurwitz S, Shah MR, et al. Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality. J Am Coll Cardiol. 2003;41:2029–2035
  42. Oster JR, Materson BJ. Renal and electrolyte complications of congestive heart failure and effects of therapy with angiotensin-converting enzyme inhibitors. Arch Intern Med. 1992;152:704–710
  43. Hsu CY, McCulloch CE, Fan D, Ordonez JD, Chertow GM. Community-based incidence of acute renal failure. Kidney Int. 2007;72:208–212
  44. Hsu CY, Ordonez JD, Chertow GM, Fan D, McCulloch CE, Go AS. The risk of acute renal failure in patients with chronic kidney disease. Kidney Int. 2008;74:101–107
  45. Liangos O, Wald R, O'Bell JW, Price L, Pereira BJ, Jaber BL. Epidemiology and outcomes of acute renal failure in hospitalized patients: A national survey. Clin J Am Soc Nephrol. 2006;1:43–51
  46. Fried LF, Biggs ML, Shlipak MG, et al. Association of kidney function with incident hip fracture in older adults. J Am Soc Nephrol. 2007;18:282–286
  47. Wattanakit K, Cushman M, Stehman-Breen C, Heckbert SR, Folsom AR. Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol. 2008;19:135–140
  48. Johnson LB, Venugopal AA, Pawlak J, Saravolatz LD. Emergence of community-associated methicillin-resistant Staphylococcus aureus infection among patients with end-stage renal disease. Infect Control Hosp Epidemiol. 2006;27:1057–1062
  49. National Kidney Foundation: Kidney Disease Outcome Quality Initiative (K/DOQI). Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(suppl):S1–S242
  50. Rind DM, Safran C, Phillips RS, et al. Effect of computer-based alerts on the treatment and outcomes of hospitalized patients. Arch Intern Med. 1994;154:1511–1517
  51. Kausz AT, Khan SS, Abichandani R, et al. Management of patients with chronic renal insufficiency in Northeastern United States. J Am Soc Nephrol. 2001;12:1501–1507
  52. McClellan WM, Knight DF, Karp H, Brown WW. Early detection and treatment of renal disease in hospitalized diabetic and hypertensive patients: Important differences between practice and published guidelines. Am J Kidney Dis. 1997;29:368–375
  53. Coresh J, Wei GL, McQuillan G, Brancati FL, Levey AS. Prevalence of high blood pressure and elevated serum creatinine level in the United States: Findings from the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med. 2001;161:1207–1216
  54. Wyatt C, Konduri V, Eng J, Rohatgi R. Reporting of estimated GFR in the primary care clinic. Am J Kidney Dis. 2007;49:634–641
  55. Rothberg MB, Kehoe ED, Courtemanche AL, et al. Recognition and management of chronic kidney disease in an elderly ambulatory population. J Gen Intern Med. 2008;23:1125–1130
  56. Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med. 1994;331:1416–1420
  57. Tepel M, van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-induced reductions in renal function with acetylcysteine. N Engl J Med. 2000;343:180–194
  58. Kucukarsian SN, Peters M, Mlynarek M, Nafziger DA. Pharmacists on rounding teams reduce preventable adverse drug events in hospital general units. Arch Intern Med. 2003;163:2014–2018
  59. Tinetti ME, Bogardus ST, Agostini JV. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N Engl J Med. 2004;351:2870–2874

 Originally published online as doi:10.1053/j.ajkd.2008.12.016 on February 27, 2009.

PII: S0272-6386(09)00030-4

doi: 10.1053/j.ajkd.2008.12.016

American Journal of Kidney Diseases
Volume 53, Issue 4 , Pages 681-688 , April 2009

Article Tools

* Image Usage & Resolution